196 related articles for article (PubMed ID: 35104870)
1. Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events.
Muir CA; Wood CCG; Clifton-Bligh RJ; Long GV; Scolyer RA; Carlino MS; Menzies AM; Tsang VHM
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1843-e1849. PubMed ID: 35104870
[TBL] [Abstract][Full Text] [Related]
2. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
[No Abstract] [Full Text] [Related]
3. Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline.
Zhou X; Iwama S; Kobayashi T; Ando M; Arima H
J Clin Endocrinol Metab; 2023 Sep; 108(10):e1056-e1062. PubMed ID: 37084392
[TBL] [Abstract][Full Text] [Related]
4. Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade.
Yamagami A; Iwama S; Kobayashi T; Zhou X; Yasuda Y; Okuji T; Ito M; Izuchi T; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Arima H
Endocr J; 2024 May; 71(5):515-526. PubMed ID: 38599854
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
6. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
7. Association between iodine intake and thyroid autoantibodies: a cross-sectional study of 7073 early pregnant women in an iodine-adequate region.
Sun J; Teng D; Li C; Peng S; Mao J; Wang W; Xie X; Fan C; Li C; Meng T; Zhang S; Du J; Gao Z; Shan Z; Teng W
J Endocrinol Invest; 2020 Jan; 43(1):43-51. PubMed ID: 31264141
[TBL] [Abstract][Full Text] [Related]
8. Thyroid peroxidase and thyroglobulin auto-antibodies in patients with newly diagnosed overt hypothyroidism.
Carlé A; Laurberg P; Knudsen N; Perrild H; Ovesen L; Rasmussen LB; Jorgensen T; Pedersen IB
Autoimmunity; 2006 Sep; 39(6):497-503. PubMed ID: 17060029
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
10. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
[TBL] [Abstract][Full Text] [Related]
11. Thyroid function in Japanese adults as assessed by a general health checkup system in relation with thyroid-related antibodies and other clinical parameters.
Kasagi K; Takahashi N; Inoue G; Honda T; Kawachi Y; Izumi Y
Thyroid; 2009 Sep; 19(9):937-44. PubMed ID: 19678737
[TBL] [Abstract][Full Text] [Related]
12. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
13. Possible added value of thyroglobulin antibody (TgAb) testing in the evaluation of thyroidal status of subjects with overweight or obesity.
Fierabracci P; Basolo A; Scartabelli G; Bechi Genzano S; Salvetti G; Sotgia G; Rotondi M; Chiovato L; Ceccarini G; Santini F
J Endocrinol Invest; 2022 Nov; 45(11):2077-2084. PubMed ID: 35781791
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis.
Osinga JAJ; Liu Y; Männistö T; Vafeiadi M; Tao FB; Vaidya B; Vrijkotte TGM; Mosso L; Bassols J; López-Bermejo A; Boucai L; Aminorroaya A; Feldt-Rasmussen U; Hisada A; Yoshinaga J; Broeren MAC; Itoh S; Kishi R; Ashoor G; Chen L; Veltri F; Lu X; Taylor PN; Brown SJ; Chatzi L; Popova PV; Grineva EN; Ghafoor F; Pirzada A; Kianpour M; Oken E; Suvanto E; Hattersley A; Rebagliato M; Riaño-Galán I; Irizar A; Vrijheid M; Delgado-Saborit JM; Fernández-Somoano A; Santa-Marina L; Boelaert K; Brenta G; Dhillon-Smith R; Dosiou C; Eaton JL; Guan H; Lee SY; Maraka S; Morris-Wiseman LF; Nguyen CT; Shan Z; Guxens M; Pop VJM; Walsh JP; Nicolaides KH; D'Alton ME; Visser WE; Carty DM; Delles C; Nelson SM; Alexander EK; Chaker L; Palomaki GE; Peeters RP; Bliddal S; Huang K; Poppe KG; Pearce EN; Derakhshan A; Korevaar TIM
Thyroid; 2024 May; 34(5):646-658. PubMed ID: 38546971
[No Abstract] [Full Text] [Related]
15. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.
Tomisti L; Urbani C; Rossi G; Latrofa F; Sardella C; Manetti L; Lupi I; Marcocci C; Bartalena L; Curzio O; Martino E; Bogazzi F
J Endocrinol Invest; 2016 May; 39(5):585-91. PubMed ID: 26759156
[TBL] [Abstract][Full Text] [Related]
16. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
Ueba Y; Yamauchi I; Hakata T; Fujita H; Okamoto K; Ikeda K; Ueda Y; Fujii T; Taura D; Inagaki N
Endocr J; 2023 Mar; 70(3):323-332. PubMed ID: 36464271
[TBL] [Abstract][Full Text] [Related]
17. Effects of Thyroperoxidase Antibody and Thyroglobulin Antibody on Maternal and Neonatal Outcomes in Pregnant Women.
Wang L; Tang Y; Yuan Y; Yu L; Jin B; Xia J; Yuan Q
Horm Metab Res; 2022 Feb; 54(2):76-83. PubMed ID: 35130568
[TBL] [Abstract][Full Text] [Related]
18. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland.
Yamauchi I; Hakata T; Sugawa T; Kosugi D; Fujita H; Okamoto K; Ueda Y; Fujii T; Taura D; Harada N; Inagaki N
Endocr J; 2023 Oct; 70(10):987-998. PubMed ID: 37574279
[TBL] [Abstract][Full Text] [Related]
19. [Distribution of IgG subclasses of TgAb and TPOAb in sera from patients with Graves' disease, Graves' disease plus Hashimoto's thyroiditis and Hashimoto's thyrotoxicosis].
Yuan S; Yu N; Gao Y; Huang W; He Y; Dong B; Lu G; Li M; Cai X; Peng D; Wang Y; Li T; Huang Y; Gao Y; Guo X; Shi B
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):110-4. PubMed ID: 24721350
[TBL] [Abstract][Full Text] [Related]
20. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
Choi YM; Kwak MK; Hong SM; Hong EG
Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
